Patent: 10,639,276

« Back to Dashboard

Summary for Patent: 10,639,276

Title:	Liposomes with ginsenoside as membrane material and preparations and use thereof
Abstract:	Among others, the present invention provides a blank liposome, preparation methods thereof, and a loaded liposome including the blank liposome and an active substance. The liposomes have a membrane comprising lipids and a ginsenoside of Formula I, and may further comprise a surfactant, a heat-sensitive excipient, a pH sensitive material, or an ion additive. ##STR00001##
Inventor(s):	Li; Chong (Shanghai, CN), Wang; Yahua (Shanghai, CN), Zhan; Huaxing (Shanghai, CN)
Assignee:	Shanghai Ginposome Pharmatech Co., Ltd. (Shanghai, CN)
Application Number:	15/300,688
Patent Claims:	see list of patent claims

Details for Patent 10,639,276

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Glaxosmithkline Biologicals	HAVRIX	hepatitis a vaccine	Injection	103475	February 22, 1995	10,639,276	2036-08-19
Glaxosmithkline Biologicals	FLUARIX, FLUARIX QUADRIVALENT	influenza vaccine	Injection	125127	August 31, 2005	10,639,276	2036-08-19
Glaxosmithkline Biologicals	FLUARIX, FLUARIX QUADRIVALENT	influenza vaccine	Injection	125127	December 14, 2012	10,639,276	2036-08-19
Id Biomedical Corporation Of Quebec	FLULAVAL, FLULAVAL QUADRIVALENT	influenza vaccine	Injection	125163	October 5, 2006	10,639,276	2036-08-19
Id Biomedical Corporation Of Quebec	FLULAVAL, FLULAVAL QUADRIVALENT	influenza vaccine	Injection	125163	November 10, 2009	10,639,276	2036-08-19
Id Biomedical Corporation Of Quebec	FLULAVAL, FLULAVAL QUADRIVALENT	influenza vaccine	Injection	125163	August 15, 2013	10,639,276	2036-08-19
Id Biomedical Corporation Of Quebec	FLULAVAL, FLULAVAL QUADRIVALENT	influenza vaccine	Injection	125163	September 27, 2013	10,639,276	2036-08-19